TCTMD: DEFINE-HF: Dapagliflozin Improves Function and Quality of Life, but Not Biomarkers, in HFrEF

A new study championed by Saint Luke's, called DEFINE-HF, which found dapagliflozin benefits heart failure patients with reduced ejection fraction (HFrEF) with and without diabetes, was recently presented at the Heart Failure Society of America (HSFA) annual meeting.

TCTMD, a publication by the Cardiovascular Research Foundation, breaks down this groundbreaking study of the new treatment option with study chair Mikhail Kosiborod, MD, director of Cardiometabolic Research at Saint Luke’s Mid America Heart Institute.

"Collectively, we believe these results support the use of dapagliflozin as a new treatment option in patients with HFrEF regardless of their diabetes status, and we believe this will result in important implications for guidelines and clinical practice," Dr. Kosiborod said.

Read the full TCTMD article, "DEFINE-HF: Dapagliflozin Improves Function and Quality of Life, but Not Biomarkers, in HFrEF". 

Related Content

doctor typing on a computer with graphs on a clipboard
Sep. 16, 2019

DEFINE-HF Trial demonstrates potential early benefits of dapagliflozin on symptoms, physical function and quality of life in patients with heart failure after 12 weeks of treatment
Trial findings shared at HFSA’s Annual Scientific Meeting Late-Breaking Clinical Trial Session
MD Magazine logo
Sep. 16, 2019

MD Magazine: Comorbidity Care with SGLT-2 Inhibition
Mikhail Kosiborod, MD, director of Cardiometabolic Research at Saint Luke’s Mid America Heart Institute, discussed where the clinical understanding of sodium-glucose co-transporter-2 inhibitors—as well as GLP-1 agonists—are stationed headed into the new dapagliflozin data.

Mikhail N Kosiborod, MD

Cardiology